A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Protocol No
REGENERON-R7075-ONC-2009
Staff Member
Stuart J Wong
Phase
I/II
Summary

The study is researching an investigational drug called REGN7075 by itself and in combination
with cemiplimab with or without chemotherapy.
Objective
The study is researching an investigational drug called REGN7075 by itself and in combination
with cemiplimab with or without chemotherapy.
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Larynx, Gastrointestinal Cancers, Lip, Oral Cavity and Pharynx, Thoracic Cancers, Breast Cancers, Head and Neck Cancers, Skin Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT04626635